Latest news

• Novartis close to US bribery settlement

  In 2015, Novartis paid $390m to settle claims related to allegations of kickbacks involving specialty pharmacy prescribing of Myfortic and thalassaemia treatment Exjade (deferasirox), without admitting any liability.

• Novartis kicks back against US corruption charges

  Last November, the company settled civil claims related to allegations of kickbacks involving specialty pharmacy prescribing of Myfortic and thalassaemia treatment Exjade (deferasirox), without admitting any liability.

• Biogen Idec taps Sangamo for blood disorder drugs

  Meanwhile, supportive therapies are also available, notably Novartis' Exjade (deferasirox) which was approved in the EU last year to manage iron overload in thalassaemia.

• Novartis' Exjade gets EU approval for thalassaemia

  For the first time, Exjade will be available to thalassemia patients who are not regularly transfused but still suffer from the life-altering effects of excess iron," he added. ... Approval in thalassaemia adds to the peak sales potential for Exjade and

• Novartis' net income up 15 per cent for Q2

  Successful launches included Exjade (deferasirox), which made $192m after receiving regulatory approvals in the US and Europe for the treatment of chronic iron overload, and Certican/Zortress (everolimus) which made $26m